SP-2509 | 9446

SP-2509 is a reversible inhibitor of Lysine-specific demethylase (LSD1) (IC₅₀ = 13 nM). It has no effect on monoamine oxidases A and B. SP2509 attenuates the binding of LSD1 to CoREST, allowing increased methylation of H3K4 and driving increased expression of p21, p27, and CCAAT/enhancer binding protein α in cultured acute myeloid leukemia (AML) cells.

SP-2509 is a reversible inhibitor of Lysine-specific demethylase (LSD1) (IC₅₀ = 13 nM). It has no effect on monoamine oxidases A and B. SP2509 attenuates the binding of LSD1 to CoREST, allowing increased methylation of H3K4 and driving increased expression of p21, p27, and CCAAT/enhancer binding protein α in cultured acute myeloid leukemia (AML) cells.

9446 | SP-2509 DataSheet

Alternate Name/Synonyms: 3-​(4-​morpholinylsulfonyl)-​benzoic acid (2E)-​2-​[1-​(5-​chloro-​2-​hydroxyphenyl)ethylidene]hydrazide

Appearance: Off-white solid

Formulation: N/A

CAS Number: 1423715-09-6

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₁₉H₂₀ClN₃O₅S

Molecular Weight: 437.9

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~25 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A reversible inhibitor of Lysine-specific demethylase (LSD1)

MDL Number: N/A

PubChem CID: 71494974

SMILES: CC(=C1C=C(C=CC1=O)Cl)NNC(=O)C2=CC(=CC=C2)S(=O)(=O)N3CCOCC3

InChi: InChI=1S/C19H20ClN3O5S/c1-13(17-12-15(20)5-6-18(17)24)21-22-19(25)14-3-2-4-16(11-14)29(26,27)23-7-9-28-10-8-23/h2-6,11-12,21H,7-10H2,1H3,(H,22,25)/b17-13-

InChi Key: ZVVCYRYDHNYAPV-LGMDPLHJSA-N